These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 37611027)

  • 21. Answering the call to address cystic fibrosis treatment burden in the era of highly effective CFTR modulator therapy.
    Gifford AH; Mayer-Hamblett N; Pearson K; Nichols DP
    J Cyst Fibros; 2020 Sep; 19(5):762-767. PubMed ID: 31761739
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CFTR Modulators: Current Status and Evolving Knowledge.
    Regard L; Martin C; Da Silva J; Burgel PR
    Semin Respir Crit Care Med; 2023 Apr; 44(2):186-195. PubMed ID: 36535667
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adherence to inhaled antibiotics in people with cystic fibrosis: insights from a virtual patient advisory board.
    Gambazza S; Storms V; Purohit V
    Expert Rev Respir Med; 2023; 17(10):961-963. PubMed ID: 37817635
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis.
    Aslam AA; Higgins C; Sinha IP; Southern KW
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD012040. PubMed ID: 28102546
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
    Southern KW; Patel S; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Timing of hypertonic saline inhalation for cystic fibrosis.
    Elkins M; Dentice R
    Cochrane Database Syst Rev; 2012 Feb; (2):CD008816. PubMed ID: 22336853
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
    Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
    Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nebulised hypertonic saline for cystic fibrosis.
    Wark PA; McDonald V; Jones AP
    Cochrane Database Syst Rev; 2005 Jul; (3):CD001506. PubMed ID: 16034863
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
    Skilton M; Krishan A; Patel S; Sinha IP; Southern KW
    Cochrane Database Syst Rev; 2019 Jan; 1(1):CD009841. PubMed ID: 30616300
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nutritional and metabolic management for cystic fibrosis in a post-cystic fibrosis transmembrane conductance modulator era.
    Wilschanski M; Peckham D
    Curr Opin Pulm Med; 2022 Nov; 28(6):577-583. PubMed ID: 36102602
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nontuberculous Mycobacteria in Cystic Fibrosis in the Era of Cystic Fibrosis Transmembrane Regulator Modulators.
    Burke A; Thomson RM; Wainwright CE; Bell SC
    Semin Respir Crit Care Med; 2023 Apr; 44(2):287-296. PubMed ID: 36649736
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cystic fibrosis clinical characteristics associated with dornase alfa treatment regimen change.
    VanDevanter DR; Craib ML; Pasta DJ; Millar SJ; Morgan WJ; Konstan MW;
    Pediatr Pulmonol; 2018 Jan; 53(1):43-49. PubMed ID: 29064184
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nebulised hypertonic saline for cystic fibrosis.
    Wark PA; McDonald V
    Cochrane Database Syst Rev; 2000; (2):CD001506. PubMed ID: 10796798
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The future of cystic fibrosis care: a global perspective.
    Bell SC; Mall MA; Gutierrez H; Macek M; Madge S; Davies JC; Burgel PR; Tullis E; Castaños C; Castellani C; Byrnes CA; Cathcart F; Chotirmall SH; Cosgriff R; Eichler I; Fajac I; Goss CH; Drevinek P; Farrell PM; Gravelle AM; Havermans T; Mayer-Hamblett N; Kashirskaya N; Kerem E; Mathew JL; McKone EF; Naehrlich L; Nasr SZ; Oates GR; O'Neill C; Pypops U; Raraigh KS; Rowe SM; Southern KW; Sivam S; Stephenson AL; Zampoli M; Ratjen F
    Lancet Respir Med; 2020 Jan; 8(1):65-124. PubMed ID: 31570318
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Can exercise replace airway clearance techniques in cystic fibrosis? A survey of patients and healthcare professionals.
    Rowbotham NJ; Smith SJ; Davies G; Daniels T; Elliott ZC; Gathercole K; Rayner OC; Smyth AR
    J Cyst Fibros; 2020 Jul; 19(4):e19-e24. PubMed ID: 31740105
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pseudomonas aeruginosa infection, but not mono or dual-combination CFTR modulator therapy affects circulating regulatory T cells in an adult population with cystic fibrosis.
    Westhölter D; Beckert H; Straßburg S; Welsner M; Sutharsan S; Taube C; Reuter S
    J Cyst Fibros; 2021 Nov; 20(6):1072-1079. PubMed ID: 34030985
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A survey: Understanding the health and perspectives of people with CF not benefiting from CFTR modulators.
    Kramer-Golinkoff E; Camacho A; Kramer L; Taylor-Cousar JL
    Pediatr Pulmonol; 2022 May; 57(5):1253-1261. PubMed ID: 35170259
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Timing of hypertonic saline inhalation for cystic fibrosis.
    Elkins M; Dentice R
    Cochrane Database Syst Rev; 2016 Dec; 12(12):CD008816. PubMed ID: 28146603
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emerging Approaches to Monitor and Modify Care in the Era of Cystic Fibrosis Transmembrane Conductance Regulators.
    Britto CJ; Ratjen F; Clancy JP
    Clin Chest Med; 2022 Dec; 43(4):631-646. PubMed ID: 36344071
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease.
    Lee TW; Southern KW
    Cochrane Database Syst Rev; 2013 Nov; (11):CD005599. PubMed ID: 24282073
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.